Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carol I. Lord is active.

Publication


Featured researches published by Carol I. Lord.


Journal of Virology | 2005

Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates

Sampa Santra; Michael S. Seaman; Ling Xu; Dan H. Barouch; Carol I. Lord; Michelle A. Lifton; Darci A. Gorgone; Kristin Beaudry; Krisha Svehla; Brent Welcher; Bimal K. Chakrabarti; Yue Huang; Zhi-Yong Yang; John R. Mascola; Gary J. Nabel; Norman L. Letvin

ABSTRACT The magnitude and durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vector-based vaccines were evaluated in the simian-human immunodeficiency virus/rhesus monkey model. A single inoculation of recombinant ADV5 vector constructs induced cellular and humoral immunity, but the rapid generation of neutralizing anti-Ad5 antibodies limited the immunity induced by repeated vector administration. The magnitude and durability of the immune responses elicited by these vaccines were greater when they were delivered as boosting immunogens in plasmid DNA-primed monkeys than when they were used as single-modality immunogens. Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.


Journal of Virology | 2001

Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys

Dan H. Barouch; Abie Craiu; Sampa Santra; Michael A. Egan; Jörn E. Schmitz; Marcelo J. Kuroda; Tong-Ming Fu; Jae-Hwan Nam; Linda S. Wyatt; Michelle A. Lifton; Georgia R. Krivulka; Christine E. Nickerson; Carol I. Lord; Bernard Moss; Mark G. Lewis; Vanessa M. Hirsch; John W. Shiver; Norman L. Letvin

ABSTRACT Increasing evidence suggests that the generation of cytotoxic T-lymphocyte (CTL) responses specific for a diversity of viral epitopes will be needed for an effective human immunodeficiency virus type 1 (HIV-1) vaccine. Here, we determine the frequencies of CTL responses specific for the simian immunodeficiency virus Gag p11C and HIV-1 Env p41A epitopes in simian-human immunodeficiency virus (SHIV)-infected and vaccinated rhesus monkeys. The p11C-specific CTL response was high frequency and dominant and the p41A-specific CTL response was low frequency and subdominant in both SHIV-infected monkeys and in monkeys vaccinated with recombinant modified vaccinia virus Ankara vectors expressing these viral antigens. Interestingly, we found that plasmid DNA vaccination led to high-frequency CTL responses specific for both of these epitopes. These data demonstrate that plasmid DNA may be useful in eliciting a broad CTL response against multiple epitopes.


Journal of Virology | 2005

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Philip R. Johnson; Bruce C. Schnepp; Mary J. Connell; Daniela Rohne; Suzanne Robinson; Georgia R. Krivulka; Carol I. Lord; Rebekah L. Zinn; David C. Montefiori; Norman L. Letvin; K. Reed Clark

ABSTRACT Gene transfer vectors based on recombinant adeno-associated virus (rAAV) are simple, versatile, and safe. While the conventional applications for rAAV vectors have focused on delivery of therapeutic genes, we have developed the system for delivery of vaccine antigens. In particular, we are interested in generating rAAV vectors for use as a prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine. To that end, we constructed vaccine vectors that expressed genes from the simian immunodeficiency virus (SIV) for evaluation in the monkey SIV model. After a single intramuscular dose, rAAV/SIV vaccines elicited SIV-specific T cells and antibodies in macaques. Furthermore, immunized animals were able to significantly restrict replication of a live, virulent SIV challenge. These data suggest that rAAV vaccine vectors induced biologically relevant immune responses, and thus, warrant continued development as a viable HIV-1 vaccine candidate.


Nature Immunology | 2005

Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants.

Dan H. Barouch; Jennifer Powers; Diana M. Truitt; Michael G. Kishko; Janelle C. Arthur; Fred W. Peyerl; Marcelo J. Kuroda; Darci A. Gorgone; Michelle A. Lifton; Carol I. Lord; Vanessa M. Hirsch; David C. Montefiori; Angela Carville; Keith G. Mansfield; Kevin J. Kunstman; Steven M. Wolinsky; Norman L. Letvin

Viral escape from cytotoxic T lymphocytes (CTLs) can undermine immune control of human immunodeficiency virus 1. It is therefore important to assess the stability of viral mutations in CTL epitopes after transmission to naive hosts. Here we demonstrate the persistence of mutations in a dominant CTL epitope after transmission of simian immunodeficiency virus variants to major histocompatibility complex–matched rhesus monkeys. Transient reversions to wild-type sequences occurred and elicited CTLs specific for the wild-type epitope, resulting in immunological pressure that rapidly reselected the mutant viruses. These data suggest that mutations in dominant human immunodeficiency virus 1 CTL epitopes may accumulate in human populations with limited major histocompatibility complex heterogeneity by a mechanism involving dynamic CTL control of transiently reverted wild-type virus.


Journal of Immunology | 2002

Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys

Sampa Santra; Jörn E. Schmitz; Marcelo J. Kuroda; Michelle A. Lifton; Christine E. Nickerson; Carol I. Lord; Ranajit Pal; Genoveffa Franchini; Norman L. Letvin

Since virus-specific CTL play a central role in containing HIV replication, a candidate AIDS vaccine should generate virus-specific CTL responses. In this study, the ability of a recombinant canarypox virus expressing SIV Gag-Pol-Env (ALVAC/SIV gag-pol-env) was assessed for its ability to elicit both dominant and subdominant epitope-specific CTL responses in rhesus monkeys. Following a series of five immunizations, memory CTL responses specific for a dominant Gag epitope could be demonstrated in the peripheral blood of vaccinated monkeys. Memory CTL responses to a subdominant Pol epitope were undetectable in these animals. Following challenge with SIVmac251, the experimentally vaccinated animals developed high frequency CTL responses specific for the dominant Gag epitope that emerged in temporal association with the early containment of viral replication. Interestingly, the experimentally vaccinated, but not the control vaccinated animals, developed CTL responses to the subdominant Pol epitope that were detectable only after containment of early viremia. Thus, recombinant canarypox vaccination elicited low frequency, but durable memory CTL populations. The temporal association of the emergence of the dominant epitope-specific response with early viral containment following challenge suggests that this immune response played a role in the accelerated clearing of early viremia in these animals. The later emerging CTL response specific for the subdominant epitope may contribute to the control of viral replication in the setting of chronic infection.


Journal of Virology | 2001

A Commonly Recognized Simian Immunodeficiency Virus Nef Epitope Presented to Cytotoxic T Lymphocytes of Indian-Origin Rhesus Monkeys by the Prevalent Major Histocompatibility Complex Class I Allele Mamu-A*02

Suzanne Robinson; William A. Charini; Michael H. Newberg; Marcelo J. Kuroda; Carol I. Lord; Norman L. Letvin

ABSTRACT The ability to monitor vaccine-elicited CD8+ cytotoxic T-lymphocyte (CTL) responses in simian immunodeficiency virus (SIV)- and simian-human immunodeficiency virus (SHIV)-infected rhesus monkeys has been limited by our knowledge of viral epitopes predictably presented to those lymphocytes by common rhesus monkey MHC class I alleles. We now define an SIV and SHIV Nef CTL epitope (YTSGPGIRY) that is presented to CD8+ T lymphocytes by the common rhesus monkey MHC class I molecule Mamu-A*02. All seven infectedMamu-A*02 + monkeys evaluated demonstrated this response, and peptide-stimulated interferon gamma Elispot assays indicated that the response represents a large proportion of the entire CD8+ T-lymphocyte SIV- or SHIV-specific immune response of these animals. Knowledge of this epitope and MHC class I allele substantially increases the number of available rhesus monkeys that can be used for testing prototype HIV vaccines in this important animal model.


Journal of Virology | 2002

Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response That Evolves in Rhesus Monkeys following a Simian-Human Immunodeficiency Virus Infection

Sampa Santra; Dan H. Barouch; Marcelo J. Kuroda; Jörn E. Schmitz; Georgia R. Krivulka; Kristin Beaudry; Carol I. Lord; Michelle A. Lifton; Linda S. Wyatt; Bernard Moss; Vanessa M. Hirsch; Norman L. Letvin

ABSTRACT Although recent evidence has confirmed the importance of cytotoxic T-lymphocyte (CTL) responses in controlling human immunodeficiency virus type 1 and simian immunodeficiency virus replication, the relevance of the epitopic breadth of those CTL responses remains unexplored. In the present study, we sought to determine whether vaccination can expand CTL populations which recognize a repertoire of viral epitopes that is greater than is typically generated in the course of a viral infection. We demonstrate that potent secondary CTL responses to subdominant epitopes are rapidly generated following a pathogenic simian-human immunodeficiency virus challenge of rhesus monkeys vaccinated with plasmid DNA or recombinant modified vaccinia virus Ankara vaccines. These data indicate that prior vaccination can increase the breadth of the CTL response that evolves after an AIDS virus infection.


Proceedings of the National Academy of Sciences of the United States of America | 1997

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination

Norman L. Letvin; David C. Montefiori; Yasuhiro Yasutomi; Helen C. Perry; Mary-Ellen Davies; Christine Lekutis; Marianne Alroy; Daniel C. Freed; Carol I. Lord; Laurence K. Handt; Margaret A. Liu; John W. Shiver


Journal of Immunology | 1999

Emergence of CTL Coincides with Clearance of Virus During Primary Simian Immunodeficiency Virus Infection in Rhesus Monkeys

Marcelo J. Kuroda; Jörn E. Schmitz; William A. Charini; Christine E. Nickerson; Michelle A. Lifton; Carol I. Lord; Meryl A. Forman; Norman L. Letvin


Nature | 1992

New recombinant HLA-B alleles in a tribe of South American Amerindians indicate rapid evolution of MHC class I loci.

David I. Watkins; Stephen N. McAdam; Xiaomin Liu; Clarice R. Strang; Edgar L. Milford; Cindy G. Levine; Theodore L. Garber; Alex L. Dogon; Carol I. Lord; Steven H. Ghim; Gary M. Troup; Austin L. Hughes; Norman L. Letvin

Collaboration


Dive into the Carol I. Lord's collaboration.

Top Co-Authors

Avatar

Norman L. Letvin

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Marcelo J. Kuroda

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Jörn E. Schmitz

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Michelle A. Lifton

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sampa Santra

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Christine E. Nickerson

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Dan H. Barouch

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William A. Charini

Beth Israel Deaconess Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge